Shuttle Pharmaceuticals Holdings Inc (SHPH) Stock Price, Quote & News

Company Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HD...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 403 4212

Website: www.shuttlepharma.com

Address:

401 Professional Drive, Suite 260, Gaithersburg, United States

vu_jade Feb. 3 at 5:13 PM

$SHPH Taking a flyer That Molecule.AI can muster some wins

0 · Reply

Zurb88 Feb. 3 at 4:12 PM

$SHPH should be moving up and down...

0 · Reply

Zurb88 Feb. 3 at 4:11 PM

$SHPH is it halted? Why staying $1.87?

1 · Reply

vu_jade Feb. 2 at 8:48 PM

$SHPH we’ll see

0 · Reply

chapelp Feb. 2 at 7:07 PM

$SHPH this is getting absolutely ridiculous !!! the only ones shorting this are the Insiders and MM with the inside information !!! ZERO shares available to short , over half million of shares shorted at 530% fee and now they get another break with the issuance of 625k shares per filling today !!! this is the 3rd time happening with this POS SCAM COMPANY , where is the SEC ?! are you guys get paid really good to sleep in your shoes !!!

1 · Reply

vu_jade Feb. 2 at 6:13 PM

$SHPH AI is the future. Molecule.AI is a new start

0 · Reply

Marko1984 Feb. 2 at 4:35 PM

$SHPH this will pop to $3.X soon

1 · Reply

InvestorAlert Feb. 2 at 4:00 PM

$SHPH green coming soon

0 · Reply

lecorb Feb. 2 at 1:54 PM

$SHPH 2/2/2026 Form: 424B3 Shuttle Pharmaceuticals Holdings, Inc. 625,156 Shares of Common Stock https://s3.amazonaws.com/sec.irpass.cc/2759/0001493152-26-004647.htm

1 · Reply

neverquitliveforever Feb. 1 at 3:45 PM

$SHPH we need news

0 · Reply

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Nov 21, 2025, 9:30 AM EST - 2 months ago

Shuttle Pharmaceuticals Acquires AI Health Platform

Nov 3, 2025, 7:00 AM EST - 3 months ago

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Oct 22, 2025, 10:00 AM EDT - 3 months ago

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Oct 22, 2025, 7:00 AM EDT - 3 months ago

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Oct 21, 2025, 5:55 PM EDT - 3 months ago

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Oct 21, 2025, 4:05 PM EDT - 3 months ago

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Oct 10, 2025, 10:20 AM EDT - 4 months ago

Shuttle Executes LOI with Molecule.ai

Oct 9, 2025, 4:15 PM EDT - 4 months ago

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Jun 24, 2025, 4:10 PM EDT - 8 months ago

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Jun 20, 2025, 3:55 PM EDT - 8 months ago

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Jun 12, 2025, 12:00 PM EDT - 8 months ago

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Jun 12, 2025, 8:30 AM EDT - 8 months ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Jun 4, 2025, 4:01 PM EDT - 8 months ago

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

May 15, 2025, 4:45 PM EDT - 9 months ago

Shuttle Pharma Provides Corporate Update

May 8, 2025, 4:01 PM EDT - 9 months ago

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Apr 21, 2025, 4:15 PM EDT - 10 months ago

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 10, 2025, 4:01 PM EDT - 10 months ago

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Mar 13, 2025, 4:10 PM EDT - 11 months ago

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 12, 2025, 9:24 AM EDT - 11 months ago

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025, 6:20 AM EDT - 11 months ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Feb 26, 2025, 10:45 AM EST - 1 year ago

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Jan 7, 2025, 9:00 AM EST - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Nov 26, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 13, 2024, 5:00 PM EST - 1 year ago

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Oct 29, 2024, 9:05 PM EDT - 1 year ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 28, 2024, 4:05 PM EDT - 1 year ago

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 4, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Aug 26, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 14, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Jun 18, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

May 22, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 14, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Apr 23, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Mar 22, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Mar 5, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Feb 13, 2024, 8:00 AM EST - 2 years ago

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Jan 23, 2024, 4:30 PM EST - 2 years ago

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 8, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Dec 11, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Nov 30, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 14, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Sep 25, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Sep 13, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

vu_jade Feb. 3 at 5:13 PM

$SHPH Taking a flyer That Molecule.AI can muster some wins

0 · Reply

Zurb88 Feb. 3 at 4:12 PM

$SHPH should be moving up and down...

0 · Reply

Zurb88 Feb. 3 at 4:11 PM

$SHPH is it halted? Why staying $1.87?

1 · Reply

vu_jade Feb. 2 at 8:48 PM

$SHPH we’ll see

0 · Reply

chapelp Feb. 2 at 7:07 PM

1 · Reply

vu_jade Feb. 2 at 6:13 PM

$SHPH AI is the future. Molecule.AI is a new start

0 · Reply

Marko1984 Feb. 2 at 4:35 PM

$SHPH this will pop to $3.X soon

1 · Reply

InvestorAlert Feb. 2 at 4:00 PM

$SHPH green coming soon

0 · Reply

lecorb Feb. 2 at 1:54 PM

$SHPH 2/2/2026 Form: 424B3 Shuttle Pharmaceuticals Holdings, Inc. 625,156 Shares of Common Stock https://s3.amazonaws.com/sec.irpass.cc/2759/0001493152-26-004647.htm

1 · Reply

neverquitliveforever Feb. 1 at 3:45 PM

$SHPH we need news

0 · Reply

neverquitliveforever Jan. 30 at 3:04 PM

$SHPH still the best kept secret very low float pops when you least expected it to

0 · Reply